All News

The identification of unique pulmonary fibrosis endotypes is an important step in the development of precision medicine approaches for the incurable condition.

The FDA approved Sandoz’ Enzeevu, the fourth aflibercept biosimilar to be approved for Americans with age-related macular degeneration and other retinal eye diseases.

The FDA has approved nemolizumab (Nemluvio; Galderma) to treat patients with prurigo nodularis based on successful phase III trials demonstrating significant reductions in itch and sleep disturbances.

The persistence of per- and polyfluoroalkyl substances (PFAS), otherwise known as "forever chemicals," poses a great threat to the environment and public health, as demonstrated by continually emerging research.

Homebound beneficiaries of a national Medicare Advantage (MA) plan had higher health service use and mortality rates, highlighting the need for tailored care strategies for this population.

Medicare Advantage (MA) enrollment has grown to 32.8 million in 2024, representing 54% of total Medicare spending, with significant variation in enrollment across states and counties.

Autologous fat grafting offers hope for patients with alopecia, especially those with scarring, by reducing inflammation and stimulating hair growth.

A Canadian study showed a high probability that using next-generation sequencing (NGS) for treatment sequencing based on risk stratification is cost-effective.

Challenges in choosing between corticosteroids and noncorticosteroids for pediatric dermatologic conditions include balancing efficacy, safety, compliance, and long-term management while considering the specific needs and risks of each child.

For the recent AIDS 2024 conference, we spoke with Nishita Dsouza, PhD, MPH, Columbia University School of Social Work Social Intervention Group, who presented research on HIV and sexually transmitted infection prevention among Black women with criminal legal system involvement.

A recent case report highlights the fatal risks of pembrolizumab, an immune checkpoint inhibitor, after an 87-year-old patient developed severe immune-related adverse events.

Medicare Advantage beneficiaries with chronic obstructive pulmonary disease (COPD) who were invited to enroll in a program that reduced inhaler costs and provided medication management had higher inhaler adherence; however, there was no significant impact on exacerbations or overall health care spending.

News surrounding different aspects of health insurance shows changes in weight loss treatment coverage, billing and claims processing errors, and customer service utilization.

In part 1 of our interview with Anna Sureda, MD, PhD, president of the European Group for Blood and Marrow Transplantation, she summarized the current treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and follicular lymphoma (FL).

Today, the FDA issued a complete response letter (CRL) for midomafetamine capsules (MDMA) in combination with assisted therapy (MDMA-AT) for adults living with posttraumatic stress disorder (PTSD).

Responders at week 104 demonstrated more significant changes from baseline and achieved normative values in PROs compared with non-responders.

The investigational therapy for heart failure (HF) with mildly reduced or preserved injection fraction met its primary end point in the phase 3 trial, Bayer announced.

Harold "Hal" Burstein, MD, PhD, emphasizes the crucial role of strong patient-physician partnerships in breast cancer treatment, empowering patients through shared decision-making.

A rundown of where Minnesota Gov Tim Walz stands on health policy issues and actions he's taken to improve health care.

David P. Carbone, MD, PhD, director of the thoracic oncology center at The Ohio State University in Columbus, discusses the importance of biomarker testing in both lung cancer overall and non–small cell lung cancer specifically.

More and more hematology factors and parameters can be analyzed with advanced equipment to better pinpoint which patients might have myelodysplastic syndromes (MDS)—but the differences in leading makers’ systems can be tricky to maneuver.

In this analysis, outcomes were investigated among 41 pediatric and young adult patients who had soft-tissue sarcoma and were aged 0 months to 22 years.

Experts argue for new mechanisms to fund research in oft-ignored rare diseases.

The involvement of 2 surgeons during cytoreductive debulking and bowel surgery in patients with epithelial ovarian cancer significantly reduces the rate of anastomotic leaks.

A high number of adverse events were reported in a late-stage trial conducted by Merck for treatment in lung cancer.

Better reporting is needed to create better guidelines for tracking infection risk in patients with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, investigators concluded.

Relapsed or refractory cutaneous t-cell lymphoma can be treated in adults with the new FDA approval of denileukin diftitox immunotherapy.

Christopher Depner, PhD, assistant professor of health and kinesiology, University of Utah, speaks to the current reliability of wearable sleep devices to impact health outcomes, privacy concerns, and more.

New data from the National Vital Statistics System show differences in mortality rates based on sex, race, and comorbidities in the United States.

Arash Mostaghimi, MD, MPA, MPH, assistant professor of dermatology, director of the inpatient dermatology consult service, and codirector of the Complex Medical Dermatology Fellowship at Brigham & Women's Hospital, discusses the recent FDA approval of deuruxolitinib for the treatment of moderate to severe alopecia areata.